98 related articles for article (PubMed ID: 8672995)
21. [Antiepileptic primidone shortly to be withdrawn from sale: change medication now].
de Haan GJ; Carpay JA; van Donselaar CA
Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2325-6. PubMed ID: 14669538
[TBL] [Abstract][Full Text] [Related]
22. Barbiturates, smoking, and bladder cancer risk.
Habel LA; Bull SA; Friedman GD
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1049-50. PubMed ID: 9829715
[TBL] [Abstract][Full Text] [Related]
23. Applicability of induced sputum for molecular dosimetry of exposure to inhalatory carcinogens: 32P-postlabeling of lipophilic DNA adducts in smokers and nonsmokers.
Besaratinia A; Maas LM; Van Breda SG; Curfs DM; Kleinjans JC; Wouters EF; Van Schooten FJ
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):367-72. PubMed ID: 10794480
[TBL] [Abstract][Full Text] [Related]
24. DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: correlations between tissues and detection by 32P-postlabelling and immunoassay.
Gyorffy E; Anna L; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Poirier MC; Schoket B
Carcinogenesis; 2004 Jul; 25(7):1201-9. PubMed ID: 15001535
[TBL] [Abstract][Full Text] [Related]
25. A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer.
Lin J; Kadlubar FF; Spitz MR; Zhao H; Wu X
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1832-6. PubMed ID: 16030125
[TBL] [Abstract][Full Text] [Related]
26. Body mass index modulates aromatic DNA adduct levels and their persistence in smokers.
Godschalk RW; Feldker DE; Borm PJ; Wouters EF; van Schooten FJ
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):790-3. PubMed ID: 12163336
[TBL] [Abstract][Full Text] [Related]
27. DNA adducts as markers of exposure and risk.
Phillips DH
Mutat Res; 2005 Sep; 577(1-2):284-92. PubMed ID: 15922369
[TBL] [Abstract][Full Text] [Related]
28. Molecular epidemiology of bladder cancer.
Vineis P; Martone T
Ann Ist Super Sanita; 1996; 32(1):21-7. PubMed ID: 8967722
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996).
Trepanier LA; Van Schoick A; Schwark WS; Carrillo J
J Am Vet Med Assoc; 1998 Nov; 213(10):1449-53. PubMed ID: 9828942
[TBL] [Abstract][Full Text] [Related]
30. Urinary tobacco-specific nitrosamines and 4-aminobiphenyl hemoglobin adducts measured in smokers of either regular or light cigarettes.
Bernert JT; Jain RB; Pirkle JL; Wang L; Miller BB; Sampson EJ
Nicotine Tob Res; 2005 Oct; 7(5):729-38. PubMed ID: 16191744
[TBL] [Abstract][Full Text] [Related]
31. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco.
Bryant MS; Vineis P; Skipper PL; Tannenbaum SR
Proc Natl Acad Sci U S A; 1988 Dec; 85(24):9788-91. PubMed ID: 3200858
[TBL] [Abstract][Full Text] [Related]
32. GSTM1 and CYP1A1 polymorphisms, tobacco, air pollution, and lung cancer: a study in rural Thailand.
Pisani P; Srivatanakul P; Randerson-Moor J; Vipasrinimit S; Lalitwongsa S; Unpunyo P; Bashir S; Bishop DT
Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):667-74. PubMed ID: 16614107
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of dimethoxymethyl phenobarbital (eterobarb) in patients with epilepsy.
Goldberg MA; Gal J; Cho AK; Jenden DJ
Ann Neurol; 1979 Feb; 5(2):121-6. PubMed ID: 426475
[TBL] [Abstract][Full Text] [Related]
34. DNA adduct burden and tobacco carcinogenesis.
Wiencke JK
Oncogene; 2002 Oct; 21(48):7376-91. PubMed ID: 12379880
[TBL] [Abstract][Full Text] [Related]
35. [Biomarkers of gentotoxic risk and metabolic polymorphism].
Pavanello S; Clonfero E
Med Lav; 2000; 91(5):431-69. PubMed ID: 11189784
[TBL] [Abstract][Full Text] [Related]
36. Interindividual variation in carcinogen metabolism and bladder cancer risk.
Vineis P; Ronco G
Environ Health Perspect; 1992 Nov; 98():95-9. PubMed ID: 1486869
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of disease: The epidemiology of bladder cancer.
Pelucchi C; Bosetti C; Negri E; Malvezzi M; La Vecchia C
Nat Clin Pract Urol; 2006 Jun; 3(6):327-40. PubMed ID: 16763645
[TBL] [Abstract][Full Text] [Related]
38. Tobacco smoking and risk of bladder cancer.
Boffetta P
Scand J Urol Nephrol Suppl; 2008 Sep; (218):45-54. PubMed ID: 18815916
[TBL] [Abstract][Full Text] [Related]
39. The use of biomarkers in epidemiology: the example of bladder cancer.
Vineis P
Toxicol Lett; 1992 Dec; 64-65 Spec No():463-7. PubMed ID: 1471198
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.
Bartsch H; Nair U; Risch A; Rojas M; Wikman H; Alexandrov K
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):3-28. PubMed ID: 10667460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
